Ernexa Therapeutics Inc. (ERNA)
ERNANASDAQ-CMBiotechnology: Pharmaceutical Preparations
$1.96
-0.1400 (-6.67%) today
Closed, Nov 10, 4:00 PM ET
- Market cap
- $3.40m
- P/E
- –
- EPS, last 4 quarters
- $-12.49
- Dividend yield
- –
- Day range
- –
- 52-week range
- $1.74 to $43.75
- Average volume
- 48.3k
- Previous close
- $2.10
Earnings
next estimate $-4.76Next report
Dec 2025
–
Mar 2026
–
Jun 2026
-3.0%
Sep 2026
+50.8%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$1.99m | -$2.09m | -$5.59m | -$4.10m |
| Net income | -$1.24m | -$1.50m | -$5.51m | -$4.01m |
News
8 latest- Ernexa Therapeutics Focuses On Clinical Readiness Of Lead Cancer Candidate RTTNews · Oct 22, 2026
- Ernexa Therapeutics Advances ERNA-101 Toward Planned Q4 2026 IND RTTNews · Sep 30, 2026
- Ernexa Reports Positive ERNA-101 Safety Data Ahead Of Q4 IND RTTNews · Sep 30, 2026
- Ernexa Selected For Emerging Track At 2026 Cell & Gene Meeting On The Mesa RTTNews · Sep 29, 2026
- Ernexa Reports Positive ERNA-201 Preclinical Data; Advances ERNA-101 Toward Q4 2026 IND RTTNews · Sep 15, 2026
- Why Now On-Demand Conference Spotlights Nine Emerging Biotech And Healthcare Stories RTTNews · Aug 29, 2026
- Top Biotech Gainers: TECH Bought Out, MSLE On Watch, KYMR Hits New High, What's The Buzz At SLS? RTTNews · Jun 25, 2026
- Ernexa Advances ERNA-101 Toward First-in-Human Study As IND Filing Nears RTTNews · Jun 17, 2026
The company
Ernexa Therapeutics (NASDAQ: ERNA) is developing innovative cell therapies for the treatment of advanced cancers. Ernexa's core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexa's allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment solution, without needing patient-specific cell harvesting. ERNA-101 is the company's lead cell therapy product, designed to activate and regulate the immune system's response to recognize and attack cancer cells. The company's initial focus is to develop ERNA-101 for the treatment of ovarian cancer, with the potential to address multiple difficult-to-treat solid tumors.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- ernexatx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.